Seres Therapeutics, Inc. (MCRB)

Seres Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	45.38	30.79	127.97	163.03	180	116.05
Short-Term Investments	-	-	-	18.31	110.7	137.57
Cash & Short-Term Investments	45.38	30.79	127.97	181.34	290.71	253.62
Cash Growth	-36.29%	-75.94%	-29.43%	-37.62%	14.62%	167.48%
Receivables	1.16	2.07	-	-	-	9.39
Prepaid Expenses	2.15	5.81	8.05	13.42	12.92	5.77
Other Current Assets	-	-	39.4	-	-	-
Total Current Assets	48.69	38.67	175.41	194.76	303.63	268.78
Property, Plant & Equipment	86.42	92.44	108.03	133.97	36.15	22.94
Long-Term Investments	-	-	-	-	0.5	49.83
Other Long-Term Assets	8.7	8.7	75.16	20.05	14.59	1.4
Total Assets	143.8	139.81	358.6	348.78	354.86	342.94
Accounts Payable	2.2	4.08	3.64	17.44	13.74	4.02
Accrued Expenses	5.81	10.72	22.51	25.07	24	14.23
Current Portion of Long-Term Debt	-	-	-	0.46	-	0.45
Current Portion of Leases	9.48	8.67	5.59	3.6	6.61	5.12
Current Unearned Revenue	-	-	-	4.26	16.82	22.6
Other Current Liabilities	13.45	17.75	66.92	34.77	21.1	-
Total Current Liabilities	30.94	41.22	98.66	85.6	82.26	46.42
Long-Term Debt	-	-	101.54	50.59	24.64	24.64
Long-Term Leases	77.96	82.97	91.65	107.94	17.96	10.56
Long-Term Unearned Revenue	-	-	-	92.43	87	85.57
Other Long-Term Liabilities	1.95	1.84	111.6	1.44	11.5	1
Total Liabilities	110.85	126.03	403.46	338	223.35	168.19
Common Stock	0.01	0.17	0.14	0.13	0.09	0.09
Additional Paid-In Capital	998.21	991.71	933.24	875.18	745.83	723.48
Retained Earnings	-965.27	-978.1	-978.24	-864.51	-614.35	-548.78
Comprehensive Income & Other	-	-	-	-0.01	-0.06	-0.05
Total Common Equity	32.95	13.78	-44.86	10.78	131.51	174.75
Shareholders' Equity	32.95	13.78	-44.86	10.78	131.51	174.75
Total Liabilities & Equity	143.8	139.81	358.6	348.78	354.86	342.94
Total Debt	87.43	91.64	198.78	162.59	49.21	40.77
Net Cash (Debt)	-42.06	-60.85	-70.82	18.75	241.5	212.85
Net Cash Growth	-	-	-	-92.23%	13.46%	325.39%
Net Cash Per Share	-5.00	-7.83	-11.07	3.47	52.67	53.35
Filing Date Shares Outstanding	8.75	8.72	7.55	6.3	4.6	4.58
Total Common Shares Outstanding	8.75	8.65	6.75	6.26	4.59	4.57
Working Capital	17.75	-2.55	76.75	109.17	221.37	222.36
Book Value Per Share	3.76	1.59	-6.64	1.72	28.62	38.21
Tangible Book Value	32.95	13.78	-44.86	10.78	131.51	174.75
Tangible Book Value Per Share	3.76	1.59	-6.64	1.72	28.62	38.21
Machinery	33.14	32.92	33.09	31.58	23.61	19.89
Construction In Progress	0.86	0.86	1.11	3.97	1.67	0.35
Leasehold Improvements	30.95	30.95	32.49	32.47	32.93	27.98

Updated Aug 6, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q